Global Cardiovascular Therapeutics Market 2024-2028
The cardiovascular therapeutics market is forecasted to grow by USD 24.25 mn during 2023-2028, accelerating at a CAGR of 4.57% during the forecast period. The report on the cardiovascular therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing risk factors for cardiovascular diseases, the availability of advanced diagnostic methods, and the rising prevalence of hypercholesterolemia.
Technavio's cardiovascular therapeutics market is segmented as below:
By Distribution Channel
- Hospital pharmacy
- Retail Pharmacy
- Online pharmacy
By Type
- Antithrombotic drugs
- Hypolipidemic drugs
- Others
By Geographical Landscape
- Asia
- North America
- Europe
- Rest of World (ROW)
This study identifies the advent of novel oral anticoagulants (NOACS) as one of the prime reasons driving the cardiovascular therapeutics market growth during the next few years. Also, the identification of new pathogenic targets related to cardiovascular diseases and the strong incidence of coronary heart disease (CHD) worldwide will lead to sizable demand in the market.
The report on the cardiovascular therapeutics market covers the following areas:
- Cardiovascular therapeutics market sizing
- Cardiovascular therapeutics market forecast
- Cardiovascular therapeutics market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading cardiovascular therapeutics market vendors that include Abbott Laboratories, Acutus Medical Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Viatris Inc., Aurobindo Pharma Ltd., and Dr Reddys Laboratories Ltd.. Also, the cardiovascular therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources through an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.